<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633358</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH104-REC3-058</org_study_id>
    <nct_id>NCT02633358</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock</brief_title>
  <official_title>Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction complicated with cardiogenic shock trigger IL-6, the strong
      inflammatory response, result in multiple organ failure, even death.

      While therapeutic hypothermia,to expect the possibility of anti-inflammatory effect via IL-6
      bi-phasic effect and IL-10 , to improve the multiple organ failure, to increase survival rate
      and well cerebral performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite emergency coronary revascularization coupled with medical stabilization, intra-aortic
      balloon pump have significantly improved survival in patients with cardiogenic shock
      complicating acute myocardial infarction, mortality still remains excessively high, being
      actually about 30-50%. Future research should focus on new therapeutic strategies, aimed to
      further decrease mortality rate of these patients or improve possible hospitalization and
      prognosis.

      Heart pumping failure result in cardiogenic shock. Increased LA filling pressure result in
      acute pulmonary edema, hypoxemic respiratory failure, even congestive kidney and congestive
      liver. Decreased stroke volume result in hypoperfusion obviously direct induce acute renal
      failure, disturbance consciousness and lactate accumulation, even, shock liver. Multiple
      organ failure is the major mortality in the patients suffered from cardiogenic shock after
      acute myocardial infarction.

      Cardiogenic shock remains the leading cause of death in patients hospitalized for myocardial
      infarction . Systemic inflammation , especially endovascular Interleukin-6, triggered by
      Tumor necrosis factor-alfa and Interleukin-1 beta result in inappropriate vasodilatation is
      observed in many patients with cardiogenic shock and may contribute to an excess mortality
      rate. In recent study, interleukin-6 represented a reliable independent early prognostic
      marker of 30-day mortality.

      Therapeutic hypothermia (34℃) increase stroke volume, reduce muscle oxygen consumption and
      enhance anti-inflammatory action . The mechanism of anti-inflammatory effect for therapeutic
      hypothermia in cardiogenic shock is still unclear, need to further study in clinical trial.
      Furthermore, this study will provide new strategy to increase survival rate in cardiogenic
      shock.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory and anti-inflammatory marker</measure>
    <time_frame>TNF-a, IL-1 b, IL-6, IL-10</time_frame>
    <description>Inflammatory and anti-inflammatory marker</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOFA</measure>
    <time_frame>SOFA score day1,3,7</time_frame>
    <description>SOFA score day1,3,7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>30-day mortality</time_frame>
    <description>30-day mortality</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Therapeutic hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 including IL-6 myo-kine(bi-phasic effect) and accompanied by IL-10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapeutic hypothermia</intervention_name>
    <description>Therapeutic hypothermia</description>
    <arm_group_label>Therapeutic hypothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 40-80 years

          -  Acute myocardial infarction

          -  Cardiogenic sock including initially systolic blood pressure&lt;90mmHg, cardiac index&lt;2.5
             Liter/m2 and hypoperfusion signs including disturbance consciousness, cold limbs,
             decreased urine output and so on.

        Exclusion Criteria:

          -  Patient or family refuse

          -  Non-myocardial infarction related cardiogenic shock

          -  Initially hypothermia (blood temperature &lt;32℃)

          -  Active uncontrolled bleeding or infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Da-Long Chen, Master</last_name>
    <role>Study Director</role>
    <affiliation>Chnia Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Da-Long Chen, Master</last_name>
    <phone>+886-4-22052121</phone>
    <phone_ext>5070</phone_ext>
    <email>my686chen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng-Chieh Lin, PhD</last_name>
    <phone>+886-4-22052121</phone>
    <phone_ext>1925</phone_ext>
    <email>irb@mail.cmuh.org.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Schmitt KR, Tong G, Berger F. Mechanisms of hypothermia-induced cell protection in the brain. Mol Cell Pediatr. 2014 Dec;1(1):7. doi: 10.1186/s40348-014-0007-x. Epub 2014 Dec 1.</citation>
    <PMID>26567101</PMID>
  </results_reference>
  <results_reference>
    <citation>Bro-Jeppesen J, Kjaergaard J, Stammet P, Wise MP, Hovdenes J, Åneman A, Horn J, Devaux Y, Erlinge D, Gasche Y, Wanscher M, Cronberg T, Friberg H, Wetterslev J, Pellis T, Kuiper M, Nielsen N, Hassager C; TTM-Trial Investigators. Predictive value of interleukin-6 in post-cardiac arrest patients treated with targeted temperature management at 33 °C or 36 °C. Resuscitation. 2016 Jan;98:1-8. doi: 10.1016/j.resuscitation.2015.10.009. Epub 2015 Oct 23.</citation>
    <PMID>26525271</PMID>
  </results_reference>
  <results_reference>
    <citation>Forkmann M, Kolschmann S, Holzhauser L, Ibrahim K, Guenther M, Christoph M, Fuhrmann JT, Boscheri A, Schmeiβer A, Strasser RH, Wunderlich C. Target temperature management of 33 degrees C exerts beneficial haemodynamic effects after out-of-hospital cardiac arrest. Acta Cardiol. 2015 Aug;70(4):451-9.</citation>
    <PMID>26455248</PMID>
  </results_reference>
  <results_reference>
    <citation>Nobile L, Lamanna I, Fontana V, Donadello K, Dell'anna AM, Creteur J, Vincent JL, Pappalardo F, Taccone FS. Greater temperature variability is not associated with a worse neurological outcome after cardiac arrest. Resuscitation. 2015 Nov;96:268-74. doi: 10.1016/j.resuscitation.2015.09.004. Epub 2015 Sep 16.</citation>
    <PMID>26386374</PMID>
  </results_reference>
  <results_reference>
    <citation>Bro-Jeppesen J, Kjaergaard J, Wanscher M, Nielsen N, Friberg H, Bjerre M, Hassager C. Systemic Inflammatory Response and Potential Prognostic Implications After Out-of-Hospital Cardiac Arrest: A Substudy of the Target Temperature Management Trial. Crit Care Med. 2015 Jun;43(6):1223-32. doi: 10.1097/CCM.0000000000000937.</citation>
    <PMID>25756419</PMID>
  </results_reference>
  <results_reference>
    <citation>Dankiewicz J, Nielsen N, Annborn M, Cronberg T, Erlinge D, Gasche Y, Hassager C, Kjaergaard J, Pellis T, Friberg H. Survival in patients without acute ST elevation after cardiac arrest and association with early coronary angiography: a post hoc analysis from the TTM trial. Intensive Care Med. 2015 May;41(5):856-64. doi: 10.1007/s00134-015-3735-z. Epub 2015 Mar 24. Erratum in: Intensive Care Med. 2015 Jun;41(6):1177.</citation>
    <PMID>25800582</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myocardial infarction, cardiogenic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

